Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab

Next Previous
X
Search
Trial Profile

A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epacadostat (Primary) ; Ipilimumab (Primary) ; Pembrolizumab (Primary) ; Retifanlimab (Primary) ; SV-BR-1-GM breast cancer vaccine BriaCell Therapeutics (Primary) ; Cyclophosphamide; Interferon alpha-2b
  • Indications Advanced breast cancer; HER2 negative breast cancer; HER2 positive breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BriaCell Therapeutics Corp

    • Most Recent Events

    • 04 Jun 2024 Results (n=54)evaluating sequencing of SV-BR-1-GM inoculation and CPI, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 03 Jun 2024 Results published in the BriaCell Therapeutics Media Release.
    • 24 Apr 2024 According to a BriaCell Therapeutics Corp media release, company today announced oral presentation of clinical data of randomized Phase 2 study evaluating Bria-IMT in patients with advanced metastatic breast cancer at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 - June 4 at McCormick Place, Chicago, IL by Saranya Chumsri, MD, Professor of Oncology, Mayo Clinic and Principal Investigator of this trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top